アクセス数 : ?
ダウンロード数 : ?
ID 115923
タイトル別表記
Sorafenib as a secondary treatment
著者
キーワード
hepatocellular carcinoma
lenvatinib
ramucirumab
regorafenib
sorafenib
資料タイプ
学術雑誌論文
抄録
Background and Aim: Currently, there is no molecular‐targeted agent that has demonstrated evidence of efficacy in patients with unresectable hepatocellular carcinoma (u‐HCC) who have developed resistance to treatment with lenvatinib (LEN). In this real‐world study, we aimed to investigate the therapeutic effect and safety of sorafenib (SOR) in patients with u‐HCC after progression on treatment with LEN.
Methods (Patients) and Results: A total of 13 patients with u‐HCC (12 males and 1 female), who were treated with SOR after progression on LEN, were enrolled in this retrospective study. Therapeutic efficacy was evaluated via contrast‐enhanced computerized tomography at 8 weeks after the initiation of SOR therapy according to modified response evaluation criteria in solid tumors (mRECIST) and RECIST. According to mRECIST, the objective response rate (ORR) and disease control rate (DCR) were 15.3% (2/13) and 69.2% (9/13), respectively. According to RECIST, the ORR and DCR were 0% (0/13) and 69.2% (9/13), respectively. The median progression‐free survival was 4.1 months. The median albumin‐bilirubin scores did not deteriorate significantly at 4, 6, and 8 weeks after initiation of SOR, compared with the scores at the baseline. The most frequent grade 1 or 2 adverse events (AEs) were palmar–plantar erythrodysesthesia, fatigue, diarrhea, and hypertension. There was no incidence of grade 3 AEs.
Conclusion: Treatment with SOR may be effective for u‐HCC after failure on LEN and may not worsen the liver reserve.
掲載誌名
JGH Open
ISSN
23979070
出版者
Journal of Gastroenterology and Hepatology Foundation|John Wiley & Sons Australia
4
6
開始ページ
1135
終了ページ
1139
発行日
2020-08-15
備考
著者名英表記誤記あり (誤)Msasahiro Sogabe→(正)Masahiro Sogabe
権利情報
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院
医学系